Do you see a potential conflict with academic medical center leaders serving as board members fro pharmaceutical companies? Well, as of 2012, this was the case for nearly 40% of drug makers worldwide and nearly EVERY U.S. pharmaceutical manufacturer. What’s being done about this? Read here to find out. (Source: Ed Silverman, The Wall Street Journal, 4/1/14).